High dose therapy followed by peripheral blood stem cell transplantation (PSCT) is a widely used therapy for relapsed or primary refractory patients with non-Hodgkin's lymphoma (NHL), however, relapses are frequent with this mode of treatment. IL-2 has shown efficacy in the treatment of patients with lymphoma. Post transplant immunotherapy with IL-2 given early after transplantation may be effective in eliminating tumor cells which survived the preparative regimen or were infused with the marrow or stem cells and thereby reduce relapses.
Showing the most recent 10 out of 1085 publications